Literature DB >> 15875218

Hyperphosphatemia in children receiving peritoneal dialysis--an educational program.

Richard T Blaszak1, Mark M Mitsnefes, Mohammad Ilyas, Scarlett D Salman, Sue M Belcher, Debbie R Brady.   

Abstract

Hyperphosphatemia has been associated with the development of secondary hyperparathyroidism, renal osteodystrophy, cardiovascular calcification and increased risk of death. Using a one group, pretest-posttest study design, we sought to evaluate changes in serum phosphorus, calcium, parathyroid hormone and subject knowledge in response to a 3-month educational intervention. Mean serum phosphorus levels did not differ significantly between the three evaluation periods: pretreatment (5.69 mg/dl), treatment (5.84 mg/dl) and posttreatment (6.17 mg/dl). Mean serum calcium, calcium-phosphorus product and PTH values also did not differ significantly between the treatment periods. We observed no difference between the subject test scores between the two testing periods. Calcium-phosphorus product, serum phosphorus and PTH values on average, despite the education program, remained outside the K/DOQI target guidelines 44, 56 and 81% of the time, respectively. The results of this study suggest that an aggressive 3-month patient education program targeting dietary phosphorus knowledge, phosphate binder name and dosing, and knowledge of medical consequences associated with non-compliance had no effect on the serum phosphorus, calcium, PTH or phosphate binder need.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875218     DOI: 10.1007/s00467-005-1884-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  31 in total

Review 1.  New developments in hyperphosphatemia management.

Authors:  Eduardo Slatopolsky
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

Review 2.  Progression of vascular calcification in uraemic patients: can it be stopped?

Authors:  Tilman B Drüeke; Stephen G Rostand
Journal:  Nephrol Dial Transplant       Date:  2002-08       Impact factor: 5.992

Review 3.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

4.  Hemodialysis and the elderly patient: potential advantages as to quality of life, urea generation, serum creatinine, and less interdialytic weight gain.

Authors:  M R Avram; C Pena; D Burrell; A Antignani; M M Avram
Journal:  Am J Kidney Dis       Date:  1990-10       Impact factor: 8.860

5.  Teaching program effects on high phosphorus levels in patients receiving hemodialysis.

Authors:  S Schlatter; C E Ferrans
Journal:  ANNA J       Date:  1998-02

6.  Pattern of noncompliance with dialysis exchanges in peritoneal dialysis patients.

Authors:  J Bernardini; M Nagy; B Piraino
Journal:  Am J Kidney Dis       Date:  2000-06       Impact factor: 8.860

7.  The effect of an educational patient compliance program on serum phosphate levels in patients receiving hemodialysis.

Authors:  N J Shaw-Stuart; A Stuart
Journal:  J Ren Nutr       Date:  2000-04       Impact factor: 3.655

Review 8.  Vascular calcification: in vitro evidence for the role of inorganic phosphate.

Authors:  Cecilia M Giachelli
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

9.  Compliance in hemodialysis patients: a multivariate regression analysis.

Authors:  G Morduchowicz; J Sulkes; S Aizic; U Gabbay; J Winkler; G Boner
Journal:  Nephron       Date:  1993       Impact factor: 2.847

10.  On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.

Authors:  E Slatopolsky; S Caglar; J P Pennell; D D Taggart; J M Canterbury; E Reiss; N S Bricker
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

View more
  1 in total

Review 1.  Interventions for metabolic bone disease in children with chronic kidney disease.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-11-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.